Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Scientific Reports|March 18, 2021
Efficiency of nilotinib to target chronic phase-chronic myeloid leukaemia primary mature CD34<sup>-</sup> and immature CD34<sup>+</sup> cellsMarc G Berger, Benjamin Lebecque, Thomas Tassin, et al.
Leukemia|July 28, 2018
European experience and risk factor analysis of donor cell-derived leukaemias/MDS following haematopoietic cell transplantationNicole Engel, Alicia Rovo, Manuela Badoglio, et al.
Leukemia Research|December 15, 2010
The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study)Bénédicte Deau, Franck E Nicolini, Joelle Guilhot, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|August 30, 2012
Measurement of imatinib uptake by flow cytometryCéline Bourgne, Mahchid Bamdad, Alexandre Janel, et al.
Oncotarget|August 19, 2015
Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML)Aminetou Mint Mohamed, Marie Balsat, Morgan Thenoz, et al.
Leukemia Research|January 27, 2009
When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group)Bruno Cassinat, Stéphane de Botton, Charikleia Kelaidi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2017
Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS StudyArnaud Pigneux, Marie C Béné, Philippe Guardiola, et al.
Blood|July 17, 2004
Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trialMathilde Hunault, Jean-Luc Harousseau, Martine Delain, et al.
Leukemia Research|February 8, 2017
TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AMLAminetou Mint Mohamed, Marie Balsat, Catherine Koering, et al.
Blood Advances|December 24, 2019
How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?Francine Garnache-Ottou, Chrystelle Vidal, Sabeha Biichlé, et al.
Pageof 6